These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 38173833)

  • 1. Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives.
    Li K; Xie G; Deng X; Zhang Y; Jia Z; Huang Z
    Front Oncol; 2023; 13():1259784. PubMed ID: 38173833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
    Kim JH; Chang IH
    Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.
    He J; Zeng X; Wang C; Wang E; Li Y
    MedComm (2020); 2024 Aug; 5(8):e671. PubMed ID: 39070179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development.
    Kwon WA; Lee SY; Jeong TY; Kim HH; Lee MK
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates in lung cancer: dawn of a new era?
    Coleman N; Yap TA; Heymach JV; Meric-Bernstam F; Le X
    NPJ Precis Oncol; 2023 Jan; 7(1):5. PubMed ID: 36631624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates for breast cancer: a bibliometric study and clinical trial analysis.
    Xing M; Li Z; Cui Y; He M; Xing Y; Yang L; Liu Z; Luo L; Wang H; Guo R
    Discov Oncol; 2024 Aug; 15(1):329. PubMed ID: 39093344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.
    Nathan P; Rajeh A; Noor M; Boldt G; Fernandes R
    Curr Oncol; 2024 Apr; 31(4):2316-2327. PubMed ID: 38668075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence.
    Gogia P; Ashraf H; Bhasin S; Xu Y
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma.
    Shih CH; Lin YH; Luo HL; Sung WW
    Front Pharmacol; 2024; 15():1326296. PubMed ID: 38572425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy.
    Riccardi F; Dal Bo M; Macor P; Toffoli G
    Front Pharmacol; 2023; 14():1274088. PubMed ID: 37790810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
    Sternschuss M; Sarfaty M
    Harefuah; 2022 Jan; 161(1):49-54. PubMed ID: 35077061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
    Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates.
    Zuo P
    AAPS J; 2020 Aug; 22(5):105. PubMed ID: 32767003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction to Antibody-Drug Conjugates.
    Pettinato MC
    Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
    Reuss JE; Rosner S; Levy BP
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):217-226. PubMed ID: 38805313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired Resistance to Antibody-Drug Conjugates.
    Collins DM; Bossenmaier B; Kollmorgen G; Niederfellner G
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30897808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.